{"componentChunkName":"component---src-templates-topic-topic-tsx","path":"/topics/multiple-myeloma/","result":{"data":{"firstChapter":{"id":"001bce70-f61f-5905-b9a0-76e49dc2928b","slug":"summary","fullItemName":"Summary","subChapters":[],"depth":1,"htmlHeader":"<!-- begin field 1cbd6b01-5c74-463c-ab08-7a2fa5a29b63 --><h1>Multiple myeloma: Summary</h1><!-- end field 1cbd6b01-5c74-463c-ab08-7a2fa5a29b63 -->","htmlStringContent":"<!-- begin item 255109be-f4b3-4859-835f-8c9a9b209c07 --><!-- begin field d0fa5643-5c5d-41d0-aacc-4404af6cd1ff --><ul><li>Multiple myeloma is a progressive malignant disease characterized by proliferation of abnormal plasma cells in the bone marrow and abnormal monoclonal immunoglobulins in the blood. It affects multiple organs and systems including the bones, kidneys, blood, and immune system.</li><li>The incidence of multiple myeloma in Europe is 4.5–6.0 per 100,000 people per year.<ul><li>Multiple myeloma is the second most common haematological malignancy in the UK. It is more common in men than in women and incidence increases with age.</li></ul></li><li>Multiple myeloma is usually an incurable disease, although advances in treatment mean that disease control can often be achieved for several years.<ul><li>The prognosis is worse if the person has high levels of serum beta-2 microglobin, high plasma cell counts, diffuse multiple bone lesions, hypercalcaemia, very high levels of M protein in blood and urine, and renal impairment.</li></ul></li><li>Complications of multiple myeloma include:<ul><li>Pathological bone fractures.</li><li>Spinal cord compression.</li><li>Renal damage.</li><li>Hypercalcaemia.</li><li>Impaired resistance to infection.</li><li>Anaemia.</li><li>Bleeding disorders.</li><li>Hyperviscosity of the blood.</li></ul></li><li>Symptoms of multiple myeloma may include:<ul><li>Bone pain, often in the lower back.</li><li>Fatigue.</li><li>Confusion, muscle weakness, constipation, thirst, and polyuria (due to hypercalcaemia).</li><li>Weight loss.</li><li>Recurrent infection.</li><li>Headache, visual disturbance, cognitive impairment, mucosal bleeding, and breathlessness (due to hyperviscosity of the blood).</li><li>Sensory loss, paraesthesia, limb weakness, walking difficulty, and sphincter disturbance (due to spinal cord compression).</li></ul></li><li>Occasionally, multiple myeloma can be asymptomatic and presents with abnormalities on blood tests such as:<ul><li>Normochromic, normocytic anaemia.</li><li>Renal impairment.</li><li>Hypercalcaemia.</li><li>Raised erythrocyte sedimentation rate (ESR), plasma viscosity, serum protein, or globulin.</li></ul></li><li>If multiple myeloma is suspected:<ul><li>Arrange a full blood count, serum calcium, and plasma viscosity or erythrocyte sedimentation rate (ESR) for people over 60 years of age with persistent bone pain, particularly back pain, or unexplained fracture.</li><li>Arrange very urgent serum electrophoresis, serum-free light chain assay, and Bence-Jones protein urine assessment (within 48 hours) for people over 60 years of age with hypercalcaemia or leukopenia, and a presentation consistent with possible myeloma.</li><li>Consider very urgent serum electrophoresis, serum-free light chain assay, and Bence-Jones protein urine assessment (within 48 hours) in people whose plasma viscosity, ESR, or incidental findings on blood tests and presentation are consistent with possible myeloma.</li><li>Also consider additional investigations including peripheral blood film, serum urea, creatinine and electrolytes, liver function tests, and for people with bone pain, X-rays of symptomatic areas (to rule out pathological fractures).</li></ul></li><li>Arrange urgent hospital admission:<ul><li>For people with symptoms of spinal cord compression.</li><li>If investigations reveal moderate to severe hypercalcaemia (corrected calcium of 2.9 mmol/L or higher) or acute kidney injury.</li></ul></li><li>Arrange urgent referral to a haematologist (within 2 weeks) for further tests to confirm the diagnosis if serum and/or urine protein electrophoresis suggest myeloma.</li><li>Secondary care treatments for multiple myeloma are dependent on the person's age, disease stage, prognosis, and comorbidities; and include:<ul><li>Bisphosphonates to reduce bone disease and pain.</li><li>Treatments for anaemia.</li><li>Chemotherapeutic drugs.</li><li>High-dose drug therapy and stem cell transplantation.</li></ul></li></ul><!-- end field d0fa5643-5c5d-41d0-aacc-4404af6cd1ff --><!-- end item 255109be-f4b3-4859-835f-8c9a9b209c07 -->","topic":{"id":"a3257bde-777f-5b48-80cd-28a6de5401b7","topicId":"d449062b-fe98-40a2-bc4d-741f0b91c31d","topicName":"Multiple myeloma","slug":"multiple-myeloma","aliases":[],"chapters":[{"id":"001bce70-f61f-5905-b9a0-76e49dc2928b","slug":"summary","fullItemName":"Summary","subChapters":[]},{"id":"a4e4ac31-e5c3-5d0d-ba8e-e28d748b38a8","slug":"have-i-got-the-right-topic","fullItemName":"Have I got the right topic?","subChapters":[]},{"id":"d731856b-56b9-5d81-9db1-6e0380152383","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?","subChapters":[{"id":"288251ee-9e56-550b-bb07-75c191dd88bb","slug":"changes","fullItemName":"Changes"},{"id":"972750f6-1493-51ac-bb67-61a883caef31","slug":"update","fullItemName":"Update"}]},{"id":"9ee3d2ca-5de2-5a81-be8d-5389cb6b96fb","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures","subChapters":[{"id":"02fc2e8c-0154-52e2-81b7-13f9f7ae4157","slug":"goals","fullItemName":"Goals"},{"id":"297bf476-1f3c-5477-859b-fc44c3d58cdd","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"ca441620-7e21-5b08-9340-cca6210d21e9","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"23d46a0d-5d23-5d38-a2d7-817babead45a","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"7f4644ec-a108-52f6-874b-8644bd8da047","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"c6fdac6a-e178-59a4-bcb7-a22337d627a4","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"c45f4611-e831-51b1-ae27-0421b247f510","slug":"background-information","fullItemName":"Background information","subChapters":[{"id":"7e70c907-9e94-5f79-b9bb-ba6799a19ccd","slug":"definition","fullItemName":"Definition"},{"id":"64fa3b9a-e0f1-5f2c-aa6b-99ca7f657bb9","slug":"prevalence","fullItemName":"Prevalence"},{"id":"222268d1-82ef-5947-9a94-81c9475bd101","slug":"risk-factors","fullItemName":"Risk Factors"},{"id":"f2cd915a-2200-5a59-9f4b-e92d4e9721d6","slug":"prognosis","fullItemName":"Prognosis"},{"id":"b84e32aa-3d7d-5e4b-a3d8-9c8cc506b4a9","slug":"complications","fullItemName":"Complications"}]},{"id":"cd2396e2-8290-5f66-ad0f-871bfebc83dd","slug":"diagnosis","fullItemName":"Diagnosis","subChapters":[{"id":"d1d186e7-f167-55b0-a9ba-20bc6df07ce9","slug":"when-should-i-suspect-multiple-myeloma","fullItemName":"When should I suspect multiple myeloma?"},{"id":"8116b468-694e-5fa4-aa60-09f23bc088e0","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"46717c89-6886-52dc-8e80-d8fb592c32b2","slug":"management","fullItemName":"Management","subChapters":[{"id":"da1a6baa-3eff-5249-bb76-6d086063c369","slug":"suspected-multiple-myeloma","fullItemName":"Scenario: Suspected multiple myeloma"},{"id":"c51edfd3-b143-5dfe-b734-2f46b572a5de","slug":"confirmed-multiple-myeloma","fullItemName":"Scenario: Confirmed multiple myeloma"},{"id":"1544f647-8ce2-51e4-adee-9cb61fc46ae1","slug":"end-stage-multiple-myeloma","fullItemName":"Scenario: End-stage multiple myeloma"}]},{"id":"375c8b98-56b6-5c85-a182-36856a3db2ca","slug":"prescribing-information","fullItemName":"Prescribing information","subChapters":[{"id":"b088260f-8cf4-5102-b99d-ab78d3ac71d3","slug":"analgesia","fullItemName":"Analgesia"}]},{"id":"ddabb890-df48-5057-a56f-32666fa74e9a","slug":"supporting-evidence","fullItemName":"Supporting evidence","subChapters":[]},{"id":"9764188e-1795-5b4f-8cdf-b70befc3fe0d","slug":"how-this-topic-was-developed","fullItemName":"How this topic was developed","subChapters":[{"id":"aef9e65b-4f13-546f-adbc-19654498aa31","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"79a1401a-ca39-5eff-ab8b-482281e9741f","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"b84ca8eb-2866-56cb-b7a1-ecb59575fddc","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"592f1670-1381-587b-baec-8618a8caf851","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"e6e2cada-c7c4-5f01-bf87-9cecee0c53f0","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"6b485c3d-36d7-556a-993b-3311a38b7bf6","slug":"references","fullItemName":"References","subChapters":[]}]}},"topic":{"id":"a3257bde-777f-5b48-80cd-28a6de5401b7","topicId":"d449062b-fe98-40a2-bc4d-741f0b91c31d","topicName":"Multiple myeloma","slug":"multiple-myeloma","aliases":[],"topicSummary":"Multiple myeloma is a progressive malignant disease of abnormal plasma cells in the bone marrow and abnormal monoclonal immunoglobulins","lastRevised":"Last revised in January 2021","nextPlannedReviewBy":"2026-01-01T00:00:00+00:00","nextPlannedReviewByDateTime":"2026-01","nextPlannedReviewByDisplay":"January 2026","specialities":[{"id":"46239e57-7990-560a-810f-b31000558649","name":"Cancer","slug":"cancer"}],"chapters":[{"id":"001bce70-f61f-5905-b9a0-76e49dc2928b","slug":"summary","fullItemName":"Summary","subChapters":[]},{"id":"a4e4ac31-e5c3-5d0d-ba8e-e28d748b38a8","slug":"have-i-got-the-right-topic","fullItemName":"Have I got the right topic?","subChapters":[]},{"id":"d731856b-56b9-5d81-9db1-6e0380152383","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?","subChapters":[{"id":"288251ee-9e56-550b-bb07-75c191dd88bb","slug":"changes","fullItemName":"Changes"},{"id":"972750f6-1493-51ac-bb67-61a883caef31","slug":"update","fullItemName":"Update"}]},{"id":"9ee3d2ca-5de2-5a81-be8d-5389cb6b96fb","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures","subChapters":[{"id":"02fc2e8c-0154-52e2-81b7-13f9f7ae4157","slug":"goals","fullItemName":"Goals"},{"id":"297bf476-1f3c-5477-859b-fc44c3d58cdd","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"ca441620-7e21-5b08-9340-cca6210d21e9","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"23d46a0d-5d23-5d38-a2d7-817babead45a","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"7f4644ec-a108-52f6-874b-8644bd8da047","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"c6fdac6a-e178-59a4-bcb7-a22337d627a4","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"c45f4611-e831-51b1-ae27-0421b247f510","slug":"background-information","fullItemName":"Background information","subChapters":[{"id":"7e70c907-9e94-5f79-b9bb-ba6799a19ccd","slug":"definition","fullItemName":"Definition"},{"id":"64fa3b9a-e0f1-5f2c-aa6b-99ca7f657bb9","slug":"prevalence","fullItemName":"Prevalence"},{"id":"222268d1-82ef-5947-9a94-81c9475bd101","slug":"risk-factors","fullItemName":"Risk Factors"},{"id":"f2cd915a-2200-5a59-9f4b-e92d4e9721d6","slug":"prognosis","fullItemName":"Prognosis"},{"id":"b84e32aa-3d7d-5e4b-a3d8-9c8cc506b4a9","slug":"complications","fullItemName":"Complications"}]},{"id":"cd2396e2-8290-5f66-ad0f-871bfebc83dd","slug":"diagnosis","fullItemName":"Diagnosis","subChapters":[{"id":"d1d186e7-f167-55b0-a9ba-20bc6df07ce9","slug":"when-should-i-suspect-multiple-myeloma","fullItemName":"When should I suspect multiple myeloma?"},{"id":"8116b468-694e-5fa4-aa60-09f23bc088e0","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"46717c89-6886-52dc-8e80-d8fb592c32b2","slug":"management","fullItemName":"Management","subChapters":[{"id":"da1a6baa-3eff-5249-bb76-6d086063c369","slug":"suspected-multiple-myeloma","fullItemName":"Scenario: Suspected multiple myeloma"},{"id":"c51edfd3-b143-5dfe-b734-2f46b572a5de","slug":"confirmed-multiple-myeloma","fullItemName":"Scenario: Confirmed multiple myeloma"},{"id":"1544f647-8ce2-51e4-adee-9cb61fc46ae1","slug":"end-stage-multiple-myeloma","fullItemName":"Scenario: End-stage multiple myeloma"}]},{"id":"375c8b98-56b6-5c85-a182-36856a3db2ca","slug":"prescribing-information","fullItemName":"Prescribing information","subChapters":[{"id":"b088260f-8cf4-5102-b99d-ab78d3ac71d3","slug":"analgesia","fullItemName":"Analgesia"}]},{"id":"ddabb890-df48-5057-a56f-32666fa74e9a","slug":"supporting-evidence","fullItemName":"Supporting evidence","subChapters":[]},{"id":"9764188e-1795-5b4f-8cdf-b70befc3fe0d","slug":"how-this-topic-was-developed","fullItemName":"How this topic was developed","subChapters":[{"id":"aef9e65b-4f13-546f-adbc-19654498aa31","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"79a1401a-ca39-5eff-ab8b-482281e9741f","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"b84ca8eb-2866-56cb-b7a1-ecb59575fddc","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"592f1670-1381-587b-baec-8618a8caf851","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"e6e2cada-c7c4-5f01-bf87-9cecee0c53f0","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"6b485c3d-36d7-556a-993b-3311a38b7bf6","slug":"references","fullItemName":"References","subChapters":[]}]}},"pageContext":{"id":"a3257bde-777f-5b48-80cd-28a6de5401b7"}},"staticQueryHashes":["3666801979"]}